Luye Pharma Group (HKSE:02186) ROE % Adjusted to Book Value : 8.36% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group ROE % Adjusted to Book Value?

Luye Pharma Group's ROE % for the quarter that ended in Jun. 2024 was 6.02%. Luye Pharma Group's PB Ratio for the quarter that ended in Jun. 2024 was 0.72. Luye Pharma Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 8.36%.

Luye Pharma Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Luye Pharma Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group ROE % Adjusted to Book Value Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

8.89

7.24

-1.43

5.59

4.56

Luye Pharma Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															7.55	5.71	2.76	6.28	8.36

Competitive Comparison of Luye Pharma Group's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's ROE % Adjusted to Book Value falls into.

Luye Pharma Group ROE % Adjusted to Book Value Calculation

Luye Pharma Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	4.65%	/	1.02
	=	4.56%

Luye Pharma Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	6.02%	/	0.72
	=	8.36%

Luye Pharma Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

LUP:Germany

Address

Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you

Luye Pharma Group Headlines

No Headlines